Nano Dimension to launch 3D bio-printing subsidiary

Nano Dimension, a 3D printing electronics company, has revealed plans to launch a subsidiary focused on solutions for end-stage renal disease, a condition that leads to kidney failure. The Israel-based company will create a platform for the 3D bio-printing of cells and connective tissues to form biological structures that function as human kidneys.  In a statement released yesterday, February 13, Amit Dror, CEO of Nano Dimension, said: "We believe that our high-end 3D printing capabilities, together with our expertise in nano-chemistry and advanced materials, provide significant added value to the promising field of bio-printing." He added that the company looks forward to bringing its know-how and intellectual property in multi-material 3D printing and integrating it into the emerging world of 3D bio-printing. Nano Dimension will advance its initiative through the new subsidiary, which will seek separate funding and be distinct from the company’s activity in the field of printed electronics.